Skip to main content

Table 1 Inclusion and exclusion criteria for febrile surveillance (clinical disease)

From: A cluster-randomized, placebo-controlled trial to evaluate the efficacy of a spatial repellent (Mosquito Shield™) against Aedes-borne virus infection among children ≥ 4–16 years of age in the Gampaha District, Sri Lanka: study protocol (the AEGIS program)

Febrile Surveillance (clinical disease)

Inclusion criteria

Exclusion criteria

Household level (written consent)

Adult head of household agrees to census, health visits, and logging resident symptoms when febrile (or in the case of suspected Zika in the absence of fever, presenting with rash, arthralgia, arthritis, or non-purulent conjunctivitis).

Individuals spend a minimum of 4 h per week during the daytime hours or sleep in the house.

Adult head of household does not agree to census, health visits, or logging symptoms of residents.

Households where study personnel identify a security risk (i.e., site where drugs are sold, residents are always drunk or hostile).

Sites where no residents spend time during the day (i.e., work 7 days a week outside the home).

Individual level (written consent)

≥ 6 months of age.

Fever at the time of presentation or report of feverishness within the previous 24 h or presenting with a rash, arthralgia, arthritis, or non-purulent conjunctivitis (suspicion of ZIKV determined by project physician).

Individual who spends a minimum of 4 h per week within the household or sleeps in the house.

<6 months of age.

No fever at time of presentation or report of feverishness within the previous 24 h or not reporting with a rash, arthralgia, arthritis, or non-purulent conjunctivitis.

Individuals who have spent less than 4 h in the household during the week prior to illness.